High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China

References

• Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–338. doi:10.1007/s12013-014-0459-625543329
   PubMed Web of Science ®Google Scholar
• Wang F, Yu ZG. Current status of breast cancer prevention in China. Chronic Dis Transl Med. 2015;1(1):2–8. doi:10.1016/j.cdtm.2015.02.00329062980
   PubMedGoogle Scholar
• Koual M, Tomkiewicz C, Cano-Sancho G, Antignac JP, Bats AS, Coumoul X. Environmental chemicals, breast cancer progression and drug resistance. Environ Health. 2020;19(1):117. doi:10.1186/s12940-020-00670-233203443
   PubMed Web of Science ®Google Scholar
• Hiatt RA, Brody JG. Environmental determinants of breast cancer. Annu Rev Public Health. 2018;39(1):113–133. doi:10.1146/annurev-publhealth-040617-01410129328875
   PubMed Web of Science ®Google Scholar
• Hu A, Li L, Hu C, et al. Serum concentrations of 15 elements among helicobacter pylori-infected residents from Lujiang County with high gastric cancer risk in Eastern China. Biol Trace Elem Res. 2018;186(1):21–30. doi:10.1007/s12011-018-1283-429502251
   PubMed Web of Science ®Google Scholar
• Gray JM, Rasanayagam S, Engel C, Rizzo J. State of the evidence 2017: an update on the connection between breast cancer and the environment. Environ Health. 2017;16:94.28865460
   PubMed Web of Science ®Google Scholar
• Van Asten K, Slembrouck L, Olbrecht S, et al. Prognostic value of the progesterone receptor by subtype in patients with estrogen receptor-positive, HER2 negative breast cancer. Oncologist. 2019;24(2):165–171. doi:10.1634/theoncologist.2018-017630171067
   PubMed Web of Science ®Google Scholar
• Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015;12(9):541–552. doi:10.1038/nrclinonc.2015.9926011489
   PubMed Web of Science ®Google Scholar
• Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504. doi:10.20892/j.issn.2095-3941.2016.006628154782
   PubMed Web of Science ®Google Scholar
• Shi J, Liu F, Song Y. Progress: targeted therapy, immunotherapy, and new chemotherapy strategies in advanced triple-negative breast cancer. Cancer Manag Res. 2020;12:9375–9387. doi:10.2147/CMAR.S27268533061626
   PubMed Web of Science ®Google Scholar
• Sawaki M, Shien T, Iwata H. TNM classification of malignant tumors (breast cancer study group). Jpn J Clin Oncol. 2019;49(3):228–231. doi:10.1093/jjco/hyy18230541035
   PubMed Web of Science ®Google Scholar
• Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609–1623.27648353
   PubMed Web of Science ®Google Scholar
• Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106–116. doi:10.7497/j.issn.2095-3941.2015.003026175926
   PubMed Web of Science ®Google Scholar
• Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer. 2014;14(1):62. doi:10.1186/1471-2407-14-6224495414
   PubMed Web of Science ®Google Scholar
• Kwong A, Mang OW, Wong CH, Chau WW, Law SC. Hong Kong breast cancer research group. Breast cancer in Hong Kong, Southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients: 1997–2001. Ann Surg Oncol. 2011;18(11):3072–3078. doi:10.1245/s10434-011-1960-421847700
   PubMed Web of Science ®Google Scholar
• Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer. 2011;11(1):292. doi:10.1186/1471-2407-11-29221749714
   PubMed Web of Science ®Google Scholar
• Du Y, Luo K, Ni R, Hussain R. Selenium and hazardous elements distribution in plant-soil-water system and human health risk assessment of Lower Cambrian, Southern Shaanxi, China. Environ Geochem Health. 2018;40(5):2049–2069. doi:10.1007/s10653-018-0082-329497886
   PubMed Web of Science ®Google Scholar
• Cann SA, van Netten JP, van Netten C. Hypothesis: iodine, selenium and the development of breast cancer. Cancer Causes Control. 2000;11(2):121–127. doi:10.1023/A:100892530145910710195
   PubMed Web of Science ®Google Scholar
• Guo D, Hendryx M, Liang X, et al. Association between selenium intake and breast cancer risk: results from the women’s health initiative. Breast Cancer Res Treat. 2020;183(1):217–226. doi:10.1007/s10549-020-05764-632607639
   PubMed Web of Science ®Google Scholar
• Zhao ZP, Yan S, Duan M, et al. Assessing heavy metal pollution and potential ecological risk of tea plantation soils. Int J Agric Biol Eng. 2019;12:185–191.
   Web of Science ®Google Scholar
• Peng L, Huang Y, Zhang J, et al. Cadmium exposure and the risk of breast cancer in Chaoshan population of southeast China. Environ Sci Pollut Res Int. 2015;22(24):19870–19878. doi:10.1007/s11356-015-5212-126289334
   PubMed Web of Science ®Google Scholar
• Gaudet HM, Christensen E, Conn B, Morrow S, Cressey L, Benoit J. Methylmercury promotes breast cancer cell proliferation. Toxicol Rep. 2018;5:579–584. doi:10.1016/j.toxrep.2018.05.00229868453
   PubMed Web of Science ®Google Scholar
• McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. J Natl Cancer Inst. 2006;98(12):869–873. doi:10.1093/jnci/djj23316788160
   PubMed Web of Science ®Google Scholar
• Chen C, Sun S, Yuan JP, et al. Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast. 2016;30:208–213. doi:10.1016/j.breast.2016.01.00427017410
   PubMed Web of Science ®Google Scholar
• Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010;21(5):961–967. doi:10.1093/annonc/mdq04120211870
   PubMed Web of Science ®Google Scholar
• Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet. 2016;387(10016):341–348. doi:10.1016/S0140-6736(15)00774-626547101
   PubMed Web of Science ®Google Scholar
• Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308–2324. doi:10.1007/s00268-010-0683-120607258
   PubMed Web of Science ®Google Scholar
• Wu Q, Ma G, Deng Y, et al. Prognostic value of ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;9:1068. doi:10.3389/fonc.2019.0106831681601
   PubMed Web of Science ®Google Scholar
• Zhu X, Chen L, Huang B, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225. doi:10.1038/s41598-019-57094-331937819
   PubMed Web of Science ®Google Scholar